Thrivent Financial for Lutherans
AMRI

Thrivent Financial for Lutherans’s Albany Molecular Research Inc AMRI Stock Holding History

Thrivent Financial for Lutherans’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-13,460
Closed -$292K – 2471
2017
Q2 		$292K Buy
13,460
+820
+6% +$14.9K ﹤0.01% 1759
2017
Q1 		$177K Buy
12,640
+650
+5% +$10.6K ﹤0.01% 1841
2016
Q4 		$225K Buy
11,990
+550
+5% +$9.35K ﹤0.01% 1801
2016
Q3 		$189K Sell
11,440
-62,480
-85% -$926K ﹤0.01% 1831
2016
Q2 		$993K Buy
73,920
+540
+0.7% +$7.88K ﹤0.01% 1098
2016
Q1 		$1.12M Sell
73,380
-38,300
-34% -$600K 0.01% 1042
2015
Q4 		$2.22M Buy
111,680
+100,330
+884% +$1.91M 0.01% 814
2015
Q3 		$198K Buy
+11,350
New +$231K ﹤0.01% 1625
2014
Q3 		– Sell
-46,650
Closed -$939K – 1907
2014
Q2 		$939K Buy
+46,650
New +$790K 0.01% 892

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Thrivent Financial for Lutherans's AMRI Position: Q3 2017 in Review

Thrivent Financial for Lutherans sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 13,460 shares — an estimated $292K sold.

Thrivent Financial for Lutherans first reported a position in AMRI in Q2 2014 and held it in 9 quarters. The position peaked at $2.22M in Q4 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Thrivent Financial for Lutherans reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 13,460 Albany Molecular Research Inc shares in Q3 2017, an estimated $292K.
  • Thrivent Financial for Lutherans first reported a position in Albany Molecular Research Inc in Q2 2014 and held it in 9 quarters.
  • Thrivent Financial for Lutherans's Albany Molecular Research Inc position peaked at $2.22M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2017, filed 14 Nov 2017.